KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Shares Outstanding (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Shares Outstanding for 14 consecutive years, with $185.5 million as the latest value for Q2 2022.

  • For the quarter ending Q2 2022, Shares Outstanding rose 1.16% year-over-year to $185.5 million, compared with a TTM value of $185.5 million through Jun 2022, up 1.16%, and an annual FY2021 reading of $183.9 million, up 1.2% over the prior year.
  • Shares Outstanding was $185.5 million for Q2 2022 at Biomarin Pharmaceutical, roughly flat from $184.9 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $185.5 million in Q2 2022 and bottomed at $176.7 million in Q1 2018.
  • Average Shares Outstanding over 5 years is $181.0 million, with a median of $181.0 million recorded in 2020.
  • The sharpest move saw Shares Outstanding increased 1.93% in 2018, then grew 0.89% in 2019.
  • Year by year, Shares Outstanding stood at $178.3 million in 2018, then increased by 0.89% to $179.8 million in 2019, then grew by 1.06% to $181.7 million in 2020, then rose by 1.2% to $183.9 million in 2021, then increased by 0.84% to $185.5 million in 2022.
  • Business Quant data shows Shares Outstanding for BMRN at $185.5 million in Q2 2022, $184.9 million in Q1 2022, and $183.9 million in Q4 2021.